Axsome Therapeutics (AXSM) News
NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
168.35-1.73 (-1.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AXSM news summary
We found 3 recent headlines mentioning Axsome Therapeutics (AXSM): 1 in the past week and 3 in the past 30 days, most often from Nasdaq. For price context, AXSM is down 1.02% at $168.35. The most recent story, "Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?", was published by Nasdaq on Oct 7, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Axsome Therapeutics headlines
- Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?Key PointsAxsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market.NasdaqAXSM, MRNA
- Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?Key PointsAxsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders.NasdaqAXSM, VRTX
- Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?Key PointsAxsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments.NasdaqAXSM, RVMD